Abstract:AIM:To study the efficacy and safety of Toric implantable contact lens(TICL)implantation in the treatment of patients with high myopia and astigmatism.
METHODS: Totally 90 patients(178 eyes)diagnosed as this disease were selected in our hospital during September 2012 to September 2016 by the method of random. The UCVA, BCVA, refraction, astigmatism coefficient, corneal endothelial cell, intraocular pressure, manifest refraction examination were accessed and compared before and after 3 and 9mo of surgery.
RESULTS: After 3 and 9mo of the surgery, the UCVA and BCVA were much higher than those before treatment, which the difference was statistically significant(P<0.05). We compared the refraction at 3mo(-0.52±0.23D)and 9mo(-0.54±0.16D), the astigmatism coefficient at 3mo(-0.39±0.23D)and 9mo(-0.33±0.56D)after treatment, and we found that the differences were not statistically significant(P>0.05). The corneal endothelial cells at 3 and 9mo after operation were compared with those of before treatment, and we found that the differences were statistically significant(P<0.05). The intraocular pressure of 3 and 9mo after operation was compared with that before operation, and we found that the differences were not statistically significant(P>0.05).
CONCLUSION: TICL implantation in the treatment of patients with high myopia and myopic astigmatism has a more obvious clinical efficacy and safety and reliability.
